Article Sidebar
Views PDF: 32
A REVIEW ON CURRENT TRENDS IN Helicobacter pylori MANAGEMENT WITH MEDICINAL PLANTS AND ITS CONSTITUENTS
Main Article Content
Abstract
Helicobacter pylori is a bacterium associated with gastric diseases and disorders of the upper gastrointestinal tract. The gram-negative bacterium Helicobacter pylori is known as a persistent colonizer of the human stomach, and this bacteria is also involved in extra-intestinal diseases. In 1994, the International Agency for Research on Cancer, World Health Organization classified H. pylori as a class 1 carcinogen, the only bacterium given this classification. Besides, the emergence of H. pylori resistance to antibiotics has been a major clinical challenge in the field of gastroenterology, and this concern has been shown an increasing tendency in many regions of the world. To overcome the current circulating difficulties, new potential therapeutic targets were uncovered to find active substances for the treatment of H. pylori infection. Several medicinal plants and their isolated compounds have been reported for their antimicrobial activity against H. pylori. It is demonstrated that they are efficacious against H. pylori strains that are resistant to drugs. The mechanism of action of many of these plant extracts and plant-derived compounds is different from that of conventional antibiotics. Therefore, natural compounds are emerging as a potential source of raw materials with diverse mechanisms of action. Some commonly known mechanisms can be listed as anti-urease activity, anti-adhesive activity, anti-inflammatory and gastroprotective activity, and effects on the oxidative stress process. Recently, new classes of drugs with reasonable antibacterial mechanisms against H. pylori have also been mentioned, including (1) anti-biofilm agents, (2) anti-virulence molecules (anti-VacA, anti-CagA agents, toxin BabA and LPS inhibitors, anti-motility agents, Helicobacter pylori quorum sensing inhibitors), (3) mucolytic agents, and (4) compounds that impact on essential proteins in the physiology of H. pylori such as inosin-5‘monophosphate dehydrogenase and HsrA inhibitors. This review article aims to summarize current prospects, identify possible novel targets, and be considered as a complementary therapy in the eradication treatment against Helicobacter pylori.
Article Details
Keywords
anti-biofilm, anti-mucolytic, anti-virulence, Helicobacter pylori, HsrA inhibitors, Inosin-5'-monophosphate dehydrogenase inhibitors
References
2. Yuan, C., et al. Research on antibiotic resistance in Helicobacter pylori: a bibliometric analysis of the past decade. Frontiers in Microbiology. 2023. 14, 1208157.
3. Bang, C.S. and G.H. Baik. Attempts to enhance the eradication rate of Helicobacter pylori infection. World J Gastroenterol. 2014. 20(18), 5252-62. doi:10.3748/wjg.v20.i18.5252.
4. Li, S., et al. How Long Will It Take to Launch an Effective Helicobacter pylori Vaccine for Humans? Infect Drug Resist. 2023. 16, 3787-3805. doi:10.2147/idr.S412361.
5. Wang, Y. Medicinal plant activity on Helicobacter pylori related diseases. World J Gastroenterol. 2014. 20(30), 10368-82. doi:10.3748/wjg.v20.i30.10368.
6. Zaidi, S., et al. Pharmacological ins and outs of medicinal plants against Helicobacter pylori: A review. Pak J Pharm Sci. 2015. 28(3), 1171-6.
7. Carron, M., et al. Identification of Helicobacter pylori Biofilms in Human Gastric Mucosa. Journal of Gastrointestinal Surgery. 2006. 10(5), 712-717. doi:https://doi.org/10.1016/j.gassur.2005.10.019.
8. Coticchia, J., et al. Presence and Density of Helicobacter pylori Biofilms in Human Gastric Mucosa in Patients With Peptic Ulcer Disease. Journal of Gastrointestinal Surgery. 2006. 10(6), 883-889. doi:https://doi.org/10.1016/j.gassur.2005.12.009.
9. Hou, C., et al. Helicobacter pylori Biofilm-Related Drug Resistance and New Developments in Its Anti-Biofilm Agents. Infect Drug Resist. 2022. 15, 1561-1571. doi:10.2147/idr.S357473.
10. Khan, S., et al. Potential utility of nano-based treatment approaches to address the risk of Helicobacter pylori. Expert Rev Anti Infect Ther. 2022. 20(3), 407-424. doi:10.1080/14787210.2022.1990041.
11. Sharndama, H. and I. Mba. Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms. Braz J Microbiol. 2022. 53(1), 33-50. doi:10.1007/s42770-02100675-0.
12. Hathroubi, S., et al. Helicobacter pylori Biofilm Formation and Its Potential Role in Pathogenesis. Microbiol Mol Biol Rev. 2018. 82(2), doi:10.1128/mmbr.00001-18.
13. Fauzia, K., et al. Biofilm Formation and Antibiotic Resistance Phenotype of Helicobacter pylori Clinical Isolates. Toxins. 2020. 12(8), 473.
14. Preda, V. and O. Săndulescu. Communication is the key: biofilms, quorum sensing, formation and prevention. Discoveries (Craiova). 2019. 7(3), e100. doi:10.15190/d.2019.13.
15. Spiegel, M., et al. In Silico Screening and In Vitro Assessment of Natural Products with Anti-
Virulence Activity against Helicobacter pylori. Molecules. 2021. 27(1), doi:10.3390/molecules27010020.
16. Xiao, S., et al. A rapid anti-Helicobacter pylori biofilm drug screening biosensor based on AlpB outer membrane protein and colloidal gold/nanoporous gold framework. Biosens Bioelectron. 2022. 215, 114599. doi:10.1016/j.bios.2022.114599.
17. Debraekeleer, A. and H. Remaut. Future perspective for potential Helicobacter pylori eradication therapies. Future Microbiol. 2018. 13, 671-687. doi:10.2217/fmb-2017-0115.
18. Naybi, M., et al., Phenolic Compounds with Anti-virulence Properties, in Phenolic Compounds,
S. Marcos, P. Mariana, and G. Maria del Rosario, Editors. 2017, IntechOpen: Rijeka. p. Chapter
8.
19. Roszczenko-Jasińska, P., M. Wojtyś, and E. Jagusztyn-Krynicka. Helicobacter pylori treatment in the post-antibiotics era—searching for new drug targets. Applied Microbiology and Biotechnology. 2020. 104(23), 9891-9905. doi:10.1007/s00253-020-10945-w.
20. Kim, S., et al. Inhibitory effects of anthocyanins on secretion of Helicobacter pylori CagA and VacA toxins. Int J Med Sci. 2012. 9(10), 838-42. doi:10.7150/ijms.5094.
21. González, A., J. Casado, and Á. Lanas. Fighting the Antibiotic Crisis: Flavonoids as Promising Antibacterial Drugs Against Helicobacter pylori Infection. Frontiers in Cellular and Infection Microbiology. 2021. 11, 1-9. doi:10.3389/fcimb.2021.709749.
22. Baj, J., et al. Helicobacter pylori Virulence Factors-Mechanisms of Bacterial Pathogenicity in the Gastric Microenvironment. Cells. 2020. 10(1), 27. doi:10.3390/cells10010027.
23. Gottesmann, M., et al. BabA and LPS inhibitors against Helicobacter pylori: pectins and pectinlike rhamnogalacturonans as adhesion blockers. Applied Microbiology and Biotechnology. 2020. 104(1), 351-363. doi:10.1007/s00253-019-10234-1.
24. Gu, H. Role of Flagella in the Pathogenesis of Helicobacter pylori. Curr Microbiol. 2017. 74(7), 863-869. doi:10.1007/s00284-017-1256-4.
25. Tharmalingam, N., et al. Inhibitory effect of piperine on Helicobacter pylori growth and adhesion to gastric adenocarcinoma cells. Infectious Agents and Cancer. 2014. 9(1), 43. doi:10.1186/17509378-9-43.
26. Suerbaum, S., et al. Identification of Antimotilins, Novel Inhibitors of Helicobacter pylori Flagellar Motility That Inhibit Stomach Colonization in a Mouse Model. mBio. 2022. 13(2), e03755-21. doi:10.1128/mbio.03755-21.
27. Bakri, W., In silico identification of potential quorum sensing inhibitors for Helicobacter pylori. 2021, Université Mohammed V
28. Boltin, D. and Y. Niv. Mucins in Gastric Cancer - An Update. J Gastrointest Dig Syst. 2013. 3(123), 15519. doi:10.4172/2161-069x.1000123.
29. Gotoh, A., et al. Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. Helicobacter. 2002. 7(3), 183-91. doi:10.1046/j.1523-5378.2002.00079.x.
30. Bang, C., et al. Additive Effect of Pronase on the Eradication Rate of First-Line Therapy for Helicobacter pylori Infection. Gut Liver. 2015. 9(3), 340-5. doi:10.5009/gnl13399.
31. Juvale, K., et al. Identification of selective inhibitors of Helicobacter pylori IMPDH as a targeted therapy for the infection. Scientific Reports. 2019. 9(1), 190. doi:10.1038/s41598-018-37490-x.
32. Juvale, K., A. Shaik, and S. Kirubakaran. Inhibitors of inosine 5′-monophosphate dehydrogenase as emerging new generation antimicrobial agents. MedChemComm. 2019. 10(8), 1290-1301.
doi:10.1039/C9MD00179D.
33. Hedstrom, L. IMP dehydrogenase: structure, mechanism, and inhibition. Chem Rev. 2009.
109(7), 2903-28. doi:10.1021/cr900021w.
34. Ghobadi, E., Z. Ghanbarimasir, and S. Emami. A review on the structures and biological activities of anti-Helicobacter pylori agents. European Journal of Medicinal Chemistry. 2021. 223, 113669. doi:https://doi.org/10.1016/j.ejmech.2021.113669.
35. González, A., et al. Identifying potential novel drugs against Helicobacter pylori by targeting the essential
response regulator HsrA. Sci Rep. 2019. 9(1), 11294. doi:10.1038/s41598-019-47746-9.